Exact Sciences/LabCorp
This article was originally published in The Gray Sheet
Executive Summary
Exclusive license for commercialization of Exact's PreGen-Plus non-invasive, genomics-based colorectal cancer screening test valued at up to $75 mil. in up-front, milestone and performance-based payments to the firm over five years, plus royalties. Announced June 27, the pact also gives LabCorp a warrant to purchase 1 mil. Exact Sciences shares over the next three years at $16.09 each...